Am Freitag bestätigte Goldman Sachs seine Kaufempfehlung für die Aktien von Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) und hielt am Kursziel von 78,00 US-Dollar fest. Der Analyst der Investmentbank ...

Discover how Ultragenyx achieved 29% revenue growth in 2024, set 2025 guidance at $640M-$670M, and advanced clinical progress toward profitability by 2027.

GC Biopharma, a South Korean biopharmaceutical company, announced on Feb. 10th that it presented development updates on its ...

Emil Kakkis; President, Chief Executive Officer, Director; Ultragenyx Pharmaceutical Inc Erik Harris; Executive Vice President, Chief Commercial Officer; Ultragenyx Pharmaceutical Inc Howard Horn; ...

Total Revenue of $560 million, exceeding guidanceCrysvita® revenue of $410 million and Dojolvi® revenue of $88 million2025 Financial ...

Truist Securities bekräftigte am Freitag seine positive Einschätzung für Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) und bestätigte sowohl die Kaufempfehlung als auch das Kursziel von 140 US-Dollar.

Good afternoon, and welcome to the Ultragenyx Fourth Quarter and Full Year 2024 Financial Results Conference Call. At this time, all participants are in a listen-only-mode. At the end of the prepared ...

Reports Q4 revenue $164.88M, consensus $158.71M. “We have created a next-generation rare disease company on a pathway to profitability with ...

Ultragenyx Pharmaceutical Inc (RARE) reports a 29% revenue increase in 2024, driven by successful product launches and international expansion, despite a significant net loss.

Goldman Sachs reiterated its Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares with a steady price target of $78.00. The firm's analyst highlighted Ultragenyx's fourth-quarter total ...